ARV-110, a proteolysis-targeting chimera, shows promising clinical activity in heavily pretreated mCRPC patients who have received at least 1 second-generation AR therapy.
Adjuvant atezolizumab did not improve disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma compared with observation.
After nearly 2 years of follow-up, pembrolizumab plus axitinib provides durable improvements in OS and PFS as compared with sunitinib in treatment-naive patients with advanced RCC.
Savolitinib demonstrated promising improvements in PFS, OS, and response rate with favorable safety outcomes vs sunitinib.
A subset of patients with advanced RCC previously treated with checkpoint inhibitors responded to subsequent treatment with nivolumab + ipilimumab.
Biomarker evaluation suggests that prolonged PFS with nivo plus ipi may be associated with enhanced expression of genes involved in the tumor microenvironment and inflammatory responses; PD-L1 expression is not predictive for OS or PFS.
PBRM1 mutations and del(9p21.3) associated with outcomes in advanced clear cell RCC treated with immune checkpoint inhibitors.
Cabozantinib plus atezolizumab resulted in durable tumor responses with tolerable toxicity in patients with urothelial carcinoma previously treated with platinum-based chemotherapy.
Combination enfortumab vedotin plus pembrolizumab demonstrated rapid, durable response, regardless of PD-L1 status, in untreated, cisplatin-ineligible patients with advanced urothelial carcinoma.
Use of antibiotics 30 days before or after starting ICI therapy in patients with advanced urothelial cancer associated with worse survival outcomes in this retrospective, exploratory analysis.
Darolutamide plus ADT led to 31% risk reduction of death vs placebo plus ADT and no new safety concerns upon longer follow-up.
Maintenance avelumab plus BSC significantly prolonged OS in the overall population and in patients with PD-L1–positive disease.